BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Lantheus Medical Imaging announced that the Food and Drug Administration (FDA) has approved a label update for Definity (perflutren lipid microsphere) injectable suspension with the removal of a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - Lantheus Holdings, Inc. (LNTH) announced the FDA has approved the supplemental new drug application for DEFINITY as an ultrasound enhancing agent for use in pediatric patients with ...
JB Chemical & Pharmaceutical recently launched Definity vial, an ultrasound contrast imaging product in India under an exclusive multi-year marketing arrangement with Lantheus Medical Imaging.
Lantheus Holdings, Inc. LNTH recently announced that the FDA has approved the supplemental new drug application for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results